ArticleJIMD reports2025
The Utility of High-Sensitivity Troponin to Detect Cardiomyopathy in Patients With Fabry Disease.
Article in JIMD reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- VCAM-1 as a biomarker of early cardiac phenotypic changes in Fabry disease.BMC cardiovascular disorders · 2026Article
- The Utility of High-Sensitivity Troponin to Detect Cardiomyopathy in Patients With Fabry Disease.JIMD reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fabry disease (FD) is an X-linked lysosomal storage disease resulting in lysosomal accumulation of glycosphingolipids in multiple organs. In this study, we (1) compare high-sensitivity cardiac troponins I and T (hs-cTnI and hs-cTnT) as markers of Fabry cardiomyopathy (FC), and (2) evaluate the role of hs-cTn in monitoring early-stage FC to establish if there is a threshold at which significant FC can be reliably excluded. Data were collected retrospectively from clinical records of adults with FD seen in the Inherited Metabolic Disorders service, Birmingham, UK. Patients with cardiac magnetic resonance imaging and concurrent hs-cTnT and/or hs-cTnI measurement(s) were included. FC was defined as the cardiac magnetic resonance imaging features of LVH and/or late gadolinium enhancement and low/pseudonormal T1. One hundred thirty-three patients (male = 54) were included (hs-cTn incidences = 259), 62 patients had significant FC, and 71 did not have FC. hs-cTnI and hs-cTnT were compared by expressing as the fractional ratio (FRTn=hs-cTn concentration/age- and sex-specific 99th percentile). The distribution of FRTnI and FRTnT was not different (median [interquartile range], 0.89 [0.52-2.02] vs. 1.02 [0.47-1.9],
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.